Strategies for the treatment of bacterial infections in the newborn
Related Experiment Videos
Insights
Antibiotic use in premature infants requires careful consideration due to unique pharmacology. Local antibiotic policies are essential for effective treatment of neonatal infections.
Area of Science:
- Neonatal pharmacology and infectious diseases.
- Microbiology and antibiotic resistance.
- Pediatric pharmacotherapy.
Background:
- Antibiotics are crucial for treating infections in premature, low birth-weight infants, often administered empirically or targeted.
- Neonatal patients have distinct pharmacological and pharmacokinetic profiles compared to older individuals.
- Bacterial infections in newborns are caused by diverse pathogens with varying geographic and hospital-specific distributions.
Purpose of the Study:
- To review general principles of antibiotic chemotherapy in neonates.
- To identify areas needing reassessment in current neonatal antibiotic practices.
- To emphasize the need for locally informed antibiotic policies.
Main Methods:
- Literature review of antibiotic use in neonatal intensive care.
- Analysis of pharmacokinetic and pharmacodynamic differences in neonates.
- Examination of evolving bacterial resistance patterns.
Main Results:
- Current antibiotics show reduced efficacy against neonatal pathogens.
- Newer agents, such as third-generation cephalosporins, offer potential improvements.
- Significant variations exist in pathogen prevalence and antibiotic susceptibility globally and between institutions.
Conclusions:
- Neonatal antibiotic therapy necessitates specialized approaches due to unique patient physiology.
- Local antibiotic stewardship programs are vital, incorporating local epidemiology and resistance data.
- Continuous re-evaluation of antibiotic practices is required to optimize neonatal care and combat resistance.
Abstract:
Antibiotics are widely used in the treatment of premature low birth-weight babies, either as blind therapy before infection is confirmed or, more specifically against a pathogen of known antibiotic susceptibility. The requirements of an antibiotic for use in the newborn are different from those in older patients and in almost every respect there are differences in the pharmacology and pharmacokinetics of antibiotics in the very young. A wide range of bacteria are responsible for infection in the new born and the distribution of these organisms will vary not only from country to country, but also from hospital to hospital. Antibiotics in current use are less effective against bacteria infecting the newborn than they once were and the introduction of new antibiotics, notably the third generation cephalosporins, provides an opportunity to reassess current antibiotic practices. This paper outlines the general considerations for chemotherapy in small babies and attempts to identify those areas where a review of current antibiotic practice is required. It is essential that decisions regarding antibiotic policies for neonatal units should be made locally and that they reflect local experience and the range of pathogens most frequently encountered and their sensitivity patterns.